AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · Missouri

HB2817

Creates provisions relating to ibogaine treatment

Status

Pending

2026 Session

IntroducedJan 7, 2026 (done)
PassedNext step (current)
Signed— (upcoming)
Law in effect— (upcoming)

Sponsor: Matthew Overcast (Republican)
Type: Therapeutic Access
Substances: Ibogaine

Official text

Summary (from PoliPsy)

Creates provisions relating to ibogaine treatment

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: house.mo.gov

Legislative history

May 7, 2026
Placed Back on Formal Perfection Calendar (H)
April 1, 2026
Committee Report
March 24, 2026
Referred
February 26, 2026
Committee Report
February 12, 2026
Referred
January 7, 2026
Introduced

Loading bill…